Sakar Healthcare Ltd. Share Price

Daily Index View : SENSEX as on 02/09/2026

1. Market Trend PROBABILITY 🚨 Current Market Trend: Positive 🚀 -5% 🔍 Key Level to Watch: 77157 🔄 Current Market Surface: The trend will stay Positive until the market stay above 77157 That’s 213 points away from the last day Closing Price of 76944 ATR 562 2. Demand & Supply PROBABILITY Force is Demand & Supply is High -15% Last 3 days market has been flatish on downside compared to ATR, so supply has very strong firepower — it just needs sentiment support 01 Sep 2026 FII Cash-net (Buy/sell) DII Cash- net (BUY/SELL) +1,143.38 +1,846.94 3. Reflexivity PROBABILITY First Half is Mildly Supportive to Bearish Momentum for at least first half -5% Last day market fell Intraday around 25–50% of the 8-day average ATR, so downside momentum should remain intact in the first half 4. Social Proof (Global) PROBABILITY Dow Jones (Last day close) 48185 Up/Donw by -317 -22% Dow jones future (live) 52,839 Up/Donw by +11.0 Hang seng (Live) 25330 Up/Donw by -253 Nikki 225 (Live) 64473 Up/Donw by -1,742 Sentiments: Dow Jones Futures is Trading Flat to Positive & HANG SENG Index is trading Negative Today, global markets are neutral to slightly positive, and the Indian market has no strong directional bias Top stock to watchout

🚀 50 Stocks With Strong Q1 FY27 Concall Commentary 📊🔥

🔹 #SGMART — 🚀 118% EBITDA growth outlook; ₹300 Cr EBITDA target for FY27 🔹 #SENORES — 💊 Targeting 30–40% revenue growth and 50–60% PAT growth in FY27 🔹 #SAKAR — 🧬 25% revenue CAGR with 50%+ PAT growth; oncology business ramp-up is a key catalyst 🔹 #SGFIN — 💰 Targeting 43% PAT growth and ₹225 Cr PAT in FY27 🔹 #SHADOWFAX — 🚚 FY27 revenue growth guidance upgraded sharply to 38–40% 🔹 #NEOGEN — 🔋 ~40% revenue growth expected, supported by battery-chemical expansion 🔹 #HFCL — 🌐 FY27 revenue growth guidance doubled to 40% from 20% 🔹 #SAHASRA — ⚡ Targeting 100% revenue growth and ₹275–300 Cr revenue in FY27 🔹 #SANGAMIND — 📈 Management targeting 100% PAT growth in FY27 🔹 #JSFB — 🏦 80%+ PAT growth outlook, with strong loan and deposit growth targets 🔹 #MOTILALOFS — 🏠 Housing finance AUM expected to grow 20%+ annually over the next 2–3 years 🔹 #BORORENEW — ☀️ Targeting 60% revenue & EBITDA growth; 600 TPD capacity expansion planned 🔹 #MBAPL — 🌾 >50% revenue growth expected in FY27, led by the Dhule SSP ramp-up 🔹 #ATLANTAELE — ⚡ Management sees ~40% revenue CAGR over the next 3 years 🔹 #NETWEB — 🖥️ 35–40% revenue growth outlook with healthy margin expectations 🔹 #SYRMA — 🔌 30–35%+ growth opportunity with strong FY27 targets 🔹 #JUBLINGREA — 🧪 32–40% EBITDA growth target; ₹750–800 Cr EBITDA outlook 🔹 #KRISHANA — 🌱 30–35% revenue growth guidance for FY27 🔹 #ARSSBL — 📊 30–35% PAT growth expected in FY27 🔹 #CGCL — 💰 30%+ AUM CAGR targeted through FY28 🔹 #SOBHA — 🏗️ 30%+ pre-sales growth target for FY27

Stocks With Strong Future Guidance — Worth Tracking

• V-Marc • RR Kabel • Finolex • HFCL

🚀 50 Stocks With Strong Q1 FY27 Concall Commentary 📊🔥

🚀 50 Stocks With Strong Q1 FY27 Concall Commentary 📊🔥 !SGMART

High-Growth Small-Cap Stocks to Track for the Next Few Years

High-Growth Small-Cap Stocks to Track for the Next Few Years Small-Cap Growth Watchlist

Sakar Healthcare Ltd operates within pharmaceutical manufacturing and contract development and manufacturing (CDMO)